MARKET

XERS

XERS

Xeris Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.040
-0.130
-5.99%
After Hours: 2.050 +0.01 +0.49% 19:49 11/29 EST
OPEN
2.230
PREV CLOSE
2.170
HIGH
2.230
LOW
2.040
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
7.94
52 WEEK LOW
1.770
MARKET CAP
254.41M
P/E (TTM)
-1.3472
1D
5D
1M
3M
1Y
5Y
Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer
DURHAM, N.C., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Barry Deutsch as chief fin...
GlobeNewswire · 11/18 13:30
GOEV, XERS and CEI among pre market gainers
Progenity PROG +20% amid social media buzz Canoo (NASDAQ:GOEV) +17%. Camber Energy (NYSE:CEI) +17%. Asia Pacific Wire & Cable APWC +14% on 1H results SPI Energy (NASDAQ:SPI) +13%. Ensysce Biosciences (NASDAQ:ENSC) +11%. Mullen
Seekingalpha · 11/17 13:33
RIOT, XERS and NNVC among pre market gainers
Creative Realities (NASDAQ:CREX) +91% industry merger creates powerful new digital signage leader EyePoint Pharmaceuticals EYPT +36% reports positive EYP-1901 data for treatment of wet AMD Bit Brother (NASDAQ:BTB) +20%. Oxbridge Re Holdings
Seekingalpha · 11/15 13:36
Xeris Pharmaceuticals Q3 EPS $(0.39) Misses $(0.37) Estimate, Sales $11.04M Beat $11.03M Estimate
Xeris Pharmaceuticals (NASDAQ:XERS) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 11.43 percent decrease over losses of $(0.35) per share
Benzinga · 11/10 12:41
Xeris Pharmaceuticals revenue in-line
Xeris Pharmaceuticals (NASDAQ:XERS): Q3 GAAP EPS of -$0.39. Revenue of $11.03M (+17.3% Y/Y) in-line. Shares +1.02% PM. Press Release As of September 30, 2021, Xeris reported total cash, cash equivalents,
Seekingalpha · 11/10 12:05
-- Earnings Flash (XERS) XERIS PHARMACEUTICALS Reports Q3 Revenue $11M, vs. Street Est of $11M
MT Newswires · 11/10 07:18
Xeris Pharmaceuticals Q3 Earnings Preview
Xeris Pharmaceuticals (NASDAQ:XERS) is scheduled to announce Q3 earnings results on Wednesday, November 10th, before market open. The consensus Revenue Estimate is $11.03M (+17.3% Y/Y). Over the last 2 years,
Seekingalpha · 11/09 16:55
Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021
CHICAGO, November 02, 2021--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Compa...
Business Wire · 11/02 11:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XERS. Analyze the recent business situations of Xeris Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average XERS stock price target is 6.25 with a high estimate of 8.00 and a low estimate of 4.250.
High8.00
Average6.25
Low4.250
Current 2.040
EPS
Actual
Estimate
-0.33-0.25-0.16-0.08
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 128
Institutional Holdings: 55.38M
% Owned: 44.40%
Shares Outstanding: 124.71M
TypeInstitutionsShares
Increased
23
4.10M
New
11
358.68K
Decreased
38
4.91M
Sold Out
38
10.99M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.73%
Pharmaceuticals & Medical Research
-0.15%
Key Executives
Chairman/Chief Executive Officer/Director
Paul Edick
President/Chief Operating Officer/Director
John Shannon
Co-Founder/Chief Scientific Officer
Steven Prestrelski
Chief Financial Officer/Director
Steven Pieper
Senior Vice President/General Counsel/Secretary/Director
Beth Hecht
Senior Vice President
Kenneth Johnson
No Data
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The Company has two products, Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis, a therapy for primary periodic paralysis. The Company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. The XeriSol formulation technology is suited for peptides and small molecules that encounter formulation challenges. The XeriJect formulation technology is suited for drugs and biologics consisting of large molecules such as proteins, monoclonal antibodies, and vaccines.

Webull offers kinds of Xeris Biopharma Holdings Inc stock information, including NASDAQ:XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.